2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775

Domenica Lorusso; Vicky Makker; Antonio Casado Herraez; Bradley J Monk; Helen Mackay; Alessandro D Santin; David S Miller; Richard Moore; Sally Baron-Hay; Isabelle Ray-Coquard; Ronnie Shapira-Frommer; Kimio Ushijima; Kan Yonemori; Yong Man Kim; Eva M Guerra Alia; Ulus A Sanli; Jie Huang; Jodi McKenzie; Gianmaria Barresi; Nicoletta Colombo

doi:10.1136/ijgc-2022-ESGO.223

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

Endometrial cancer

2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775

Free

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password